Sign In
Buy ALNY
$297.69
+5.53 (+1.89%)
At Close: Jun 09, 2026
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $90.00 Price Target at SVB Leerink
01:52am, Tuesday, 11'th Aug 2020
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective lifted by SVB Leerink from $89.00 to $90.00 in a research report sent to investors on Friday, BenzingaRatingsTable reports. They currently
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
12:00am, Tuesday, 11'th Aug 2020
The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance
02:56pm, Friday, 07'th Aug 2020
Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
Coronavirus update: U.S. case tally climbs above 4.8 million as Trump contradicts health experts to claim virus will ‘go away’
05:42pm, Thursday, 06'th Aug 2020
The number of confirmed cases of the coronavirus that causes COVID-19 in the U.S. rose above 4.8 million on Thursday, a day after President Donald Trump...
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
03:25pm, Thursday, 06'th Aug 2020
Alnylam (ALNY) delivered earnings and revenue surprises of 12.85% and 5.34%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity
12:00pm, Thursday, 06'th Aug 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business highligh
Alnylam Announces Planned Transition of Barry Greene, President
11:30am, Thursday, 06'th Aug 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that after 17 years, Barry Greene, President, has decided to leave the Company at the end of the th
Alnylam Announces Planned Transition of Barry Greene, President
12:00am, Thursday, 06'th Aug 2020
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that after 17 years, Barry Greene, President, has
ValuEngine Upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to “Buy”
06:20am, Wednesday, 05'th Aug 2020
Alnylam Pharmaceuticals (NASDAQ:ALNY) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Monday, ValuEngine reports. A number of oth
IPO Update: Freeline Therapeutics Proposes Terms For U.S. IPO (Pending:FRLN)
05:44pm, Monday, 03'rd Aug 2020
Freeline Therapeutics Holdings plc has filed to raise $125 million in a U.S. IPO.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines an
Dyne Therapeutics Appoints Susanna High as Chief Operating Officer
12:00am, Monday, 03'rd Aug 2020
Dyne Therapeutics today announced that it has appointed Susanna High, MBA, as its chief operating officer.
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
04:33pm, Thursday, 30'th Jul 2020
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
